Journal of labelled compounds and radiopharmaceuticals p. 174 - 182 (2020)
Update date:2022-08-05
Topics:
Kang, Julie
Lee, Jun Young
Park, Jeong-Hoon
Chang, Dong-Jo
Imatinib (Gleevec) is a multiple tyrosine kinase inhibitor that decreases the activity of the fusion oncogene called BCR-ABL (breakpoint cluster region protein-Abelson murine leukemia viral oncogene homolog) and is clinically used for the treatment of chronic myelogenous leukemia and acute lymphocytic leukemia. Small molecule drugs, such as imatinib, can bind to several cellular proteins including the target proteins in the cells, inducing undesirable effects along with the effects against the disease. In this study, we report the synthetic optimization for 14C-labeling and radiosynthesis of [14C]imatinib to analyze binding with cellular proteins using accelerator mass spectroscopy. 14C-labeling of imatinib was performed by the synthesis of 14C-labeld 2-aminopyrimidine intermediate using [14C]guanidine·HCl, which includes an in situ reduction of an inseparable byproduct for easy purification by HPLC, followed by a cross-coupling reaction with aryl bromide precursor. The radiosynthesis of [14C]imatinib (specific activity, 631 MBq/mmol; radiochemical purity, 99.6%) was achieved in six steps with a total chemical yield of 29.2%.
View MoreHangzhou yi lu biont technology Co., LTD
Contact:+86-571-88152630
Address:Hangzhoushi HuafengRoad Yicheng3Building1001room.
Hunan Shineway Enterprise Co., Ltd.
Contact:+86-731-86303875
Address:118, Huanghua International Airport Road, Huanghua Town, Changsha, Hunan 410137, China
Hangzhou Mole's Science & Technology Co.,Ltd.(expird)
Contact:+86-571-56880228
Address:15F Guodu development Building, NO.182 Zhaohui Road
Contact:+86-0760-85282375
Address:zhongjing road,zhongshan torch hi-tech industrial development zone
Guangzhou Chemical Reagent Factory
Contact:+86-20-8435 9820 or 8435 7345
Address:Southern Guangzhou, Guangdong, China
Doi:10.1055/s-0028-1087804
(2009)Doi:10.1002/ejic.200500892
(2006)Doi:10.1016/S0040-4020(01)96597-4
(1985)Doi:10.1021/ac00277a056
(1984)Doi:10.1002/hlca.200690202
(2006)Doi:10.1002/anie.201604986
(2016)